Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
PaperCitations, authors & open-access status
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 282 citations, 2023 year and green oa status.
282
Citations
2023
Year
green
OA Status